Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0011570 (
depression
)
172,036
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Disrupted in schizophrenia 1
(
DISC1
) is one of the most convincing genetic risk factors for major mental illness identified to date.
DISC1
interacts directly with phosphodiesterase 4B (PDE4B), an independently identified risk factor for schizophrenia.
DISC1
-PDE4B complexes are therefore likely to be involved in molecular mechanisms underlying psychiatric illness. PDE4B hydrolyses cAMP and
DISC1
may regulate cAMP signalling through modulating PDE4B activity. There is evidence that expression of both genes is altered in some psychiatric patients. Moreover,
DISC1
missense mutations that give rise to phenotypes related to schizophrenia and
depression
in mice are located within binding sites for PDE4B. These mutations reduce the association between
DISC1
and PDE4B, and one results in reduced brain PDE4B activity. Altered
DISC1
-PDE4B interaction may thus underlie the symptoms of some cases of schizophrenia and
depression
. Factors likely to influence this interaction include expression levels, binding site affinities and the
DISC1
and PDE4 isoforms involved.
DISC1
and PDE4 isoforms are targeted to specific subcellular locations which may contribute to the compartmentalization of cAMP signalling. Dysregulated cAMP signalling in specific cellular compartments may therefore be a predisposing factor for major mental illness.
...
PMID:Disrupted in schizophrenia 1 and phosphodiesterase 4B: towards an understanding of psychiatric illness. 1782 7